Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia
Background As a malignancy of hematopoietic origin, the standard-of-care cytoreductive chemotherapy can not provide satisfactory treatment effect for patients with acute myeloid leukemia (AML). Immunotherapy has received increasing attention in leukemia treatment. However, the immunosuppressive micr...
Saved in:
| Main Authors: | Jing Yang, Ling Zhang, Nan Wu, Jiayuan Hu, Jun Ren, Xinyi Chen, Xingyu Wei, Minghui Sun, Ziwei Li, Yongcan Liu, Yan Shu, Genyou Li, Fangfang Jin, Can Lin, Lisha Tang, Zesong Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/7/e011148.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NRF2 maintains redox balance via ME1 and NRF2 inhibitor synergizes with venetoclax in NPM1-mutated acute myeloid leukemia
by: Jiayuan Hu, et al.
Published: (2025-06-01) -
Doxing: The Sandy Hook Case Study
by: Daria Bulgakova
Published: (2025-01-01) -
Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy
by: Sampat Singh Tanwar, et al.
Published: (2025-03-01) -
The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response
by: Xuanyu Guo, et al.
Published: (2024-12-01) -
Myeloid-derived suppressor cell inhibits T-cell-based defense against Klebsiella pneumoniae infection via IDO1 production.
by: Qi Xu, et al.
Published: (2025-03-01)